The DOI matches its Crossref record; 128 of the 129 references it cites were found in a registry or an index.
The blockade of immune checkpoints in cancer immunotherapy
Open accessAbstract
Among the most promising approaches to activating therapeutic antitumour immunity is the blockade of immune checkpoints. Immune checkpoints refer to a plethora of inhibitory pathways hardwired into the immune system that are crucial for maintaining self-tolerance and modulating the duration and amplitude of physiological immune responses in peripheral tissues in order to minimize collateral tissue damage. It is now clear that tumours co-opt certain immune-checkpoint pathways as a major mechanism of immune resistance, particularly against T cells that are specific for tumour antigens. Because many of the immune checkpoints are initiated by ligand-receptor interactions, they can be readily blocked by antibodies or modulated by recombinant forms of ligands or receptors. Cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) antibodies were the first of this class of immunotherapeutics to achieve US Food and Drug Administration (FDA) approval. Preliminary clinical findings with blockers of additional immune-checkpoint proteins, such as programmed cell death protein 1 (PD1), indicate broad and diverse opportunities to enhance antitumour immunity with the potential to produce durable clinical responses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recently, immunotherapies have shown promising results for reducing metastasis in melanoma or kidney cancer patients[1, 2].”
From Microfluidics: A New Tool for Modeling Cancer–Immune Interactions (2016) · cites this paper as [2]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Under normal physiological conditions, inhibitory immune checkpoint molecules are essential to maintain self-tolerance and prevent autoimmunity [1,2]”
From Characterizing the molecular regulation of inhibitory immune checkpoints with multimodal single-cell screens (2021) · cites this paper as [2]
In the citing paper
“there was strong down-regulation of several proteins with potential roles in modifying the response to immunotherapies exclusively in co-culture conditions, including CXCR4 (CD184), c-KIT (CD117) and KDR (CD309)23,24”
From Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasion (2021) · cites this paper as [23]
In the citing paper
“There is an active imbalance between stimulatory and inhibitory B7 family members in the tumor microenvironment [1,3,7,8].”
From T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment (2013) · cites this paper as [3]
In the citing paper
“Furthermore, TGF-β signaling in T cells activates SHP1 expression, which represses protein tyrosine kinase activities required for TCR signaling203,204.”
From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [204]
In the citing paper
“In monotherapy, checkpoint inhibitors have resulted in impressive effects and durable responses in patients with highly refractory and late-stage cancers, such as metastatic melanoma and non-small cell lung cancer (NSCLC) [216].”
From Three decades of messenger RNA vaccine development (2019) · cites this paper as [216]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Control of Regulatory T Cell Development by the Transcription Factor Foxp3
Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells
Fontenot, J. D., Gavin, M. A., & Rudensky, A. Y. (2003) · Nature Immunology · doi:10.1038/ni904 · Cited by 7,745
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2005) · Nature · doi:10.1038/nature04444 · Cited by 4,057
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Flagged first, then by citations
1 of the 129 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Taube, J. M. et al. B7-H1 expression co-localizes with inflammatory infiltrates in benign and malignant melanocytic lesions: implications for immunotherapy. Sci. Transl. Med. (In the press, 2012). Introduction of the adaptive immune resistance hypothesis that proposes that the expression of immune-checkpoint ligand by tumours can be induced by an antitumour immune response as an adaptive immune-protective mechanism.
Cited by
Sorted by citations
Items 701–800 of 1,126
Baer, C., Squadrito, M. L., Laoui, D., Thompson, D., Hansen, S. K., Kiialainen, A., Hoves, S., Ries, C. H., Ooi, C.-H., & De Palma, M. (2016) · Nature Cell Biology · doi:10.1038/ncb3371 · Cited by 259
Novel immunotherapies in lymphoid malignancies
Batlevi, C. L., Matsuki, E., Brentjens, R. J., & Younes, A. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.187 · Cited by 264
Soluble immune checkpoints in cancer: production, function and biological significance
Gu, D., Ao, X., Yang, Y. P., Chen, Z., & Xu, X. M. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0449-0 · Cited by 259
Workel, H. H., Lubbers, J. M., Arnold, R. R., Prins, T. M., van der Vlies, P., de Lange, K., Bosse, T., van Gool, I. C., Eggink, F. A., Wouters, M. C. A., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0517 · Cited by 266
Villalobos, P. A., & Wistuba, I. I. (2016) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2016.08.006 · Cited by 268
Immune Cell–Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation
Bald, T., Landsberg, J., Lopez-Ramos, D., Renn, M., Glodde, N., Jansen, P., Gaffal, E., Steitz, J., Tolba, R. H., Kalinke, U., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0458 · Cited by 261
Effector, Memory, and Dysfunctional CD8+T Cell Fates in the Antitumor Immune Response
Reiser, J., & Banerjee, A. (2016) · Journal of Immunology Research · doi:10.1155/2016/8941260 · Cited by 262
Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade
Jacquelot, N., Yamazaki, T., Roberti, M. P., Duong, C. P. M., Andrews, M. C., Verlingue, L., Ferrere, G., Becharef, S., Vétizou, M., Daillère, R., et al. (2019) · Cell Research · doi:10.1038/s41422-019-0224-x · Cited by 263
Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors
Harris, D. T., & Kranz, D. M. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.11.004 · Cited by 262
Ilié, M., Hofman, V., Dietel, M., Soria, J., & Hofman, P. M. (2016) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-016-1910-4 · Cited by 258
Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma
Quispel-Janssen, J. M. M. F., van der Noort, V., de Vries, J. F., Zimmerman, M., Lalezari, F., Thunnissen, E., Monkhorst, K., Schouten, R. D., Schunselaar, L. M., Disselhorst, M., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.05.038 · Cited by 259
Yang, W., Zhang, F., Deng, H., Lin, L., Wang, S., Kang, F., Yu, G., Lau, J., Tian, R., Zhang, M., et al. (2019) · ACS Nano · doi:10.1021/acsnano.9b07212 · Cited by 254
Krupka, C., Kufer, P., Kischel, R., Zugmaier, G., Lichtenegger, F. S., Köhnke, T., Vick, B., Jeremias, I., Metzeler, K. H., Altmann, T., et al. (2015) · Leukemia · doi:10.1038/leu.2015.214 · Cited by 256
Li, J., Jie, H.-B., Lei, Y. L., Gildener‐Leapman, N., Trivedi, S., Green, T., Kane, L., & Ferris, R. L. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1215 · Cited by 256
Mazzaschi, G., Madeddu, D., Falco, A., Bocchialini, G., Goldoni, M., Sogni, F., Armani, G., Lagrasta, C. A., Lorusso, B., Mangiaracina, C., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2156 · Cited by 254
Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC
Grant, M. J., Herbst, R. S., & Goldberg, S. B. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00520-1 · Cited by 257
Targeting T cell metabolism for therapy
O’Sullivan, D., & Pearce, E. L. (2015) · Trends in Immunology · doi:10.1016/j.it.2014.12.004 · Cited by 261
Cancer stem cell plasticity and tumor hierarchy
Cabrera, M. C. (2015) · World Journal of Stem Cells · doi:10.4252/wjsc.v7.i1.27 · Cited by 264
Antitumor Activity of cGAMP via Stimulation of cGAS-cGAMP-STING-IRF3 Mediated Innate Immune Response
Li, T., Cheng, H., Yuan, H., Xu, Q., Shu, C., Zhang, Y., Xu, P., Tan, J., Rui, Y., Li, P., et al. (2016) · Scientific Reports · doi:10.1038/srep19049 · Cited by 251
Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
Lee, H. T., Lee, J., Lim, H., Lee, S. H., Moon, Y. J., Pyo, H. J., Ryu, S. E., Shin, W., & Heo, Y.-S. (2017) · Scientific Reports · doi:10.1038/s41598-017-06002-8 · Cited by 259
Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy
Lee, N., Zakka, L. R., Mihm, M. C., & Schatton, T. (2016) · Pathology · doi:10.1016/j.pathol.2015.12.006 · Cited by 250
The Lymphatic System in Disease Processes and Cancer Progression
Padera, T. P., Meijer, E. F. J., & Munn, L. L. (2016) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-112315-031200 · Cited by 249
Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition
del Alcazar, C. R. G., Huh, S. J., Ekram, M. B., Trinh, A. C., Liu, L. L., de Beça, F. F., Zi, X., Kwak, M., Bergholtz, H., Su, Y., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0222 · Cited by 255
Translational control of tumor immune escape via the eIF4F–STAT1–PD-L1 axis in melanoma
Cerezo, M., Guemiri, R., Druillennec, S., Girault, I., Malka-Mahieu, H., Shen, S., Allard, D., Martineau, S., Welsch, C., Agoussi, S., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0217-1 · Cited by 257
Therapeutic targeting of regulatory T cells in cancer
Shan, F., Somasundaram, A., Bruno, T. C., Workman, C. J., & Vignali, D. A. A. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.06.008 · Cited by 255
Legat, A., Speiser, D. E., Pircher, H., Zehn, D., & Marraco, S. A. F. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00455 · Cited by 248
Zhao, X., Suryawanshi, S., Hruska, M. W., Feng, Y., Wang, X., Shen, J., Vezina, H. E., McHenry, M. B., Waxman, I. M., Achanta, A., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx235 · Cited by 250
Single-cell transcriptomic analysis of tissue-resident memory T cells in human lung cancer
Clarke, J. D., Panwar, B., Madrigal, A., Singh, D. K., Gujar, R., Wood, O., Chee, S., Eschweiler, S., King, E. V., Awad, A. S., et al. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20190249 · Cited by 255
Molecular and Cellular Functions of CTLA-4
Coillie, S. V., Wiernicki, B., & Xu, J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-3266-5_2 · Cited by 259
Cardiotoxicity of immune checkpoint inhibitors
Varricchi, G., Galdiero, M. R., Marone, G., Criscuolo, G., Triassi, M., Bonaduce, D., Marone, G., & Tocchetti, C. G. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000247 · Cited by 247
Microsatellite instability: an update
Yamamoto, H., & Imai, K. (2015) · Archives of Toxicology · doi:10.1007/s00204-015-1474-0 · Cited by 247
Chen, T. W., Razak, A. R. A., Bedard, P. L., Siu, L. L., & Hansen, A. R. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv182 · Cited by 247
Darb‐Esfahani, S., Kunze, C. A., Kulbe, H., Sehouli, J., Wienert, S., Lindner, J., Budczies, J., Bockmayr, M. L., Dietel, M., Denkert, C., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6429 · Cited by 252
Bioinspired and Biomimetic Nanomedicines
Chen, Z., Wang, Z., & Gu, Z. (2019) · Accounts of Chemical Research · doi:10.1021/acs.accounts.9b00079 · Cited by 246
Hot and cold tumors: Immunological features and the therapeutic strategies
Wang, L., Geng, H., Liu, Y., Liu, L., Chen, Y., Wu, F., Liu, Z., Ling, S., Wang, Y., & Zhou, L. (2023) · MedComm · doi:10.1002/mco2.343 · Cited by 261
Anti-programmed cell death protein-1/ligand-1 therapy in different cancers
Moreno, B. H., & Ribas, A. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.124 · Cited by 252
Predictive Markers for the Efficacy of Anti–PD-1/PD-L1 Antibodies in Lung Cancer
Shukuya, T., & Carbone, D. P. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.02.015 · Cited by 249
Teng, F., Meng, X., Kong, L., & Yu, J. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.11.014 · Cited by 249
Li, J., Li, W., Huang, K., Zhang, Y., Kupfer, G. M., & Zhao, Q. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0568-6 · Cited by 251
Guerriero, J. L. (2018) · International review of cytology · doi:10.1016/bs.ircmb.2018.07.001 · Cited by 256
Paver, E. C., Cooper, W. A., Colebatch, A. J., Ferguson, P. M., Hill, S. K., Lum, T., Shin, J., O’Toole, S. A., Anderson, L. A., Scolyer, R. A., et al. (2020) · Pathology · doi:10.1016/j.pathol.2020.10.007 · Cited by 252
Harnessing Nanomaterials for Cancer Sonodynamic Immunotherapy
Liang, S., Yao, J., Liu, D., Rao, L., Chen, X. S., & Wang, Z. (2023) · Advanced Materials · doi:10.1002/adma.202211130 · Cited by 245
NLRP3 signaling drives macrophage-induced adaptive immune suppression in pancreatic carcinoma
Daley, D., Mani, V. R., Mohan, N., Akkad, N., Pandian, G. S. D. B., Savadkar, S., Lee, K. B., Torres-Hernandez, A., Aykut, B., Diskin, B., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20161707 · Cited by 244
Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab
de Filette, J., Jansen, Y., Schreuer, M., Everaert, H., Velkeniers, B., Neyns, B., & Bravenboer, B. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2300 · Cited by 244
Metallic nanoparticles for cancer immunotherapy
Evans, E. R., Bugga, P., Asthana, V., & Drezek, R. A. (2017) · Materials Today · doi:10.1016/j.mattod.2017.11.022 · Cited by 248
Self‐Amplified Drug Delivery with Light‐Inducible Nanocargoes to Enhance Cancer Immunotherapy
Feng, B., Hou, B., Xu, Z., Saeed, M., Yu, H., & Li, Y. (2019) · Advanced Materials · doi:10.1002/adma.201902960 · Cited by 245
Belcaid, Z., Phallen, J. A., Zeng, J., See, A. P., Mathios, D., Gottschalk, C., Nicholas, S. E., Kellett, M. D., Ruzevick, J., Jackson, C. M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101764 · Cited by 246
Self-citationThe Journey from Discoveries in Fundamental Immunology to Cancer Immunotherapy
Miller, J. F. A. P., & Sadelain, M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.007 · Cited by 246
Targeted therapies for renal cell carcinoma
Posadas, E. M., Limvorasak, S., & Figlin, R. A. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.82 · Cited by 246
Liu, Y., Liu, X., Zhang, N., Yin, M., Dong, J., Zeng, Q., Mao, G., Song, D., Liu, L., & Deng, H. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.06.014 · Cited by 243
How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer
Stultz, J., & Fong, L. (2021) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-021-00340-5 · Cited by 242
Inhibitory Receptors Beyond T Cell Exhaustion
Marraco, S. A. F., Neubert, N. J., Verdeil, G., & Speiser, D. E. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00310 · Cited by 250
The Immune Biology of Microsatellite-Unstable Cancer
Kloor, M., & Doeberitz, M. V. K. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.02.004 · Cited by 245
Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy
Blake, S. J., Stannard, K. A., Liu, J., Allen, S. M., Yong, M. C. R., Mittal, D., Aguilera, A. R., Miles, J. J., Lutzky, V. P., de Andrade, L. F., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0944 · Cited by 252
Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis
Wang, Y., Abu‐Sbeih, H., Mao, E., Ali, N., Qiao, W., Trinh, V. A., Zobniw, C. M., Johnson, D. H., Samdani, R. T., Lum, P. J., et al. (2018) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izy104 · Cited by 245
YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma
Kim, M. H., Kim, C. G., Kim, S.-K., Shin, S. J., Choe, E. A., Park, S.-H., Shin, E.-C., & Kim, J. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0320 · Cited by 241
Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment
Liu, G., Rui, W., Zhao, X., & Lin, X. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00655-2 · Cited by 244
Choi, Y. Y., Kim, H., Shin, S., Kim, H. Y., Lee, J., Yang, H., Kim, W. H., Kim, Y., Kook, M., Park, Y. K., et al. (2018) · Annals of Surgery · doi:10.1097/sla.0000000000002803 · Cited by 243
Wang, X., Yang, X., Zhang, C., Wang, Y., Cheng, T., Duan, L., Tong, Z., Tan, S., Zhang, H., Saw, P. E., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1921445117 · Cited by 245
Ahmed, K. A., Stallworth, D. G., Kim, Y., Johnstone, P. A. S., Harrison, L. B., Caudell, J. J., Yu, H., Etame, A. B., Weber, J. S., & Gibney, G. T. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv622 · Cited by 240
Treatment of Relapsed/Refractory Acute Myeloid Leukemia
Bose, P., Vachhani, P. J., & Cortes, J. E. (2017) · Current Treatment Options in Oncology · doi:10.1007/s11864-017-0456-2 · Cited by 241
Stenzinger, A., Allen, J. D., Maas, J., Stewart, M. D., Merino, D. M., Wempe, M. M., & Dietel, M. (2019) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22733 · Cited by 245
Chao, Y., Liang, C., Tao, H., Du, Y., Wu, D., Dong, Z., Jin, Q., Chen, G., Xu, J., Xiao, Z., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz4204 · Cited by 239
Papalexi, E., Mimitou, E. P., Butler, A. W., Foster, S., Bracken, B., Mauck, W. M., Wessels, H.-H., Hao, Y., Yeung, B. Z., Smibert, P., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00778-2 · Cited by 237
Cell membrane coated-nanoparticles for cancer immunotherapy
Zeng, Y., Li, S., Zhang, S., Wang, L., Yuan, H., & Hu, F. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.02.023 · Cited by 238
OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal
Linch, S. N., McNamara, M. J., & Redmond, W. L. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00034 · Cited by 243
Hallmarks of response to immune checkpoint blockade
Cogdill, A. P., Andrews, M. C., & Wargo, J. A. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.136 · Cited by 251
Hypersialylation in Cancer: Modulation of Inflammation and Therapeutic Opportunities
Rodrigues, E., & Macauley, M. S. (2018) · Cancers · doi:10.3390/cancers10060207 · Cited by 238
Raja, R. G., Kuziora, M. A., Brohawn, P. Z., Higgs, B. W., Gupta, A. K., Dennis, P. A., & Ranade, K. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0386 · Cited by 240
Treg-mediated acquired resistance to immune checkpoint inhibitors
Saleh, R., & Elkord, E. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.05.003 · Cited by 242
Immune checkpoints in the tumor microenvironment
Toor, S. M., Nair, V. S., Decock, J. V., & Elkord, E. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.06.021 · Cited by 242
A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1
Ngiow, S. F., Young, A., Jacquelot, N., Yamazaki, T., Enot, D., Zitvogel, L., & Smyth, M. J. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1082 · Cited by 237
Immune checkpoint inhibitor–associated myocarditis: manifestations and mechanisms
Moslehi, J., Lichtman, A. H., Sharpe, A. H., Galluzzi, L., & Kitsis, R. N. (2021) · Journal of Clinical Investigation · doi:10.1172/jci145186 · Cited by 237
Weinmann, S. C., & Pisetsky, D. S. (2019) · Rheumatology · doi:10.1093/rheumatology/kez308 · Cited by 243
Fatty Acid Oxidation Controls CD8+ Tissue-Resident Memory T-cell Survival in Gastric Adenocarcinoma
Lin, R., Zhang, H., Yuan, Y., He, Q., Zhou, J., Li, S., Sun, Y., Li, D. Y., Qiu, H.-B., Wang, W., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0702 · Cited by 242
Cancer Immunotherapy: A Future Paradigm Shift in the Treatment of Non–Small Cell Lung Cancer
Anagnostou, V., & Brahmer, J. R. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1187 · Cited by 239
The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment
Pennock, G. K., & Chow, L. Q. M. (2015) · The Oncologist · doi:10.1634/theoncologist.2014-0422 · Cited by 241
In Situ Dendritic Cell Vaccine for Effective Cancer Immunotherapy
Yang, W., Zhu, G., Wang, S., Yu, G., Yáng, Z., Lin, L., Zhou, Z., Liu, Y., Dai, Y., Zhang, F., et al. (2019) · ACS Nano · doi:10.1021/acsnano.8b08346 · Cited by 237
Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology
Lee, H. T., Lee, S. H., & Heo, Y. (2019) · Molecules · doi:10.3390/molecules24061190 · Cited by 244
Francis, D. M., Manspeaker, M. P., Schudel, A., Sestito, L. F., O’Melia, M. J., Kissick, H. T., Pollack, B. P., Waller, E. K., & Thomas, S. N. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay3575 · Cited by 240
Macrophages and microglia: the cerberus of glioblastoma
Buonfiglioli, A., & Hambardzumyan, D. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01156-z · Cited by 254
Liu, S., Foulkes, W. D., Leung, S., Gao, D., Lau, S., Kos, Z., & Nielsen, T. O. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0432-8 · Cited by 236
Tarhini, A. A. (2013) · Scientifica · doi:10.1155/2013/857519 · Cited by 239
Immunotherapy of Hepatocellular Carcinoma: Facts and Hopes
Iñarrairaegui, M., Melero, I., & Sangro, B. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0289 · Cited by 235
Clinical development of targeted and immune based anti-cancer therapies
Seebacher, N. A., Stacy, A. E., Porter, G., & Merlot, A. M. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1094-2 · Cited by 241
Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities
Tahir, S. A., Gao, J., Miura, Y., Blando, J. M., Tidwell, R. S. S., Zhao, H., Subudhi, S. K., Tawbi, H. A., Keung, E. Z.-Y., Wargo, J. A., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1908079116 · Cited by 238
Badwelan, M., Muaddi, H. A., Ahmed, A., Lee, K. T., & Tran, S. D. (2023) · Current Oncology · doi:10.3390/curroncol30040283 · Cited by 235
The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer
Gevensleben, H., Dietrich, D., Golletz, C., Steiner, S., Jung, M., Thiesler, T., Majores, M., Stein, J., Uhl, B., Müller, S., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2042 · Cited by 239
Resistance to cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes
Zhu, J., de Tenbossche, C. P., Canè, S., Colau, D., van Baren, N., Lurquin, C., Schmitt‐Verhulst, A., Liljeström, P., Uyttenhove, C., & den Eynde, B. J. V. (2017) · Nature Communications · doi:10.1038/s41467-017-00784-1 · Cited by 237
CAR therapy: the CD19 paradigm
Sadelain, M. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80010 · Cited by 238
Lee, J. M., Lee, M.-H., Garon, E. B., Goldman, J. W., Salehi‐Rad, R., Baratelli, F. E., Schaue, D., Wang, G., Rosen, F., Yanagawa, J., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2821 · Cited by 233
Etzerodt, A., Tsalkitzi, K., Maniecki, M. B., Damsky, W., Delfini, M., Baudoin, E., Moulin, M., Bosenberg, M., Graversen, J. H., Auphan‐Anezin, N., et al. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20182124 · Cited by 242
Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation
Braaten, T. J., Brahmer, J. R., Forde, P. M., Le, D., Lipson, E. J., Naidoo, J., Schollenberger, M., Zheng, L., Bingham, C. O., Shah, A. A., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-216109 · Cited by 230
Multiplexed Epitope-Based Tissue Imaging for Discovery and Healthcare Applications
Bodenmiller, B. (2016) · Cell Systems · doi:10.1016/j.cels.2016.03.008 · Cited by 235
Selby, M., Engelhardt, J., Johnston, R. J., Lu, L.-S., Han, M., Thudium, K. B., Yao, D., Quigley, M. M., Valle, J., Wang, C., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0161779 · Cited by 236
Engineering universal cells that evade immune detection
Lanza, R., Russell, D. W., & Nagy, A. (2019) · Nature reviews. Immunology · doi:10.1038/s41577-019-0200-1 · Cited by 238
Designing nanomedicine for immuno-oncology
Jiang, W., Roemeling, C. A. V., Chen, Y., Qie, Y., Liu, X., Chen, J., & Kim, B. Y. S. (2017) · Nature Biomedical Engineering · doi:10.1038/s41551-017-0029 · Cited by 230
Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade
Zhang, F., Wei, H., Wang, X., Bai, Y., Wang, P., Wu, J., Jiang, X., Wang, Y., Cai, H., Xu, T., et al. (2017) · Cell Discovery · doi:10.1038/celldisc.2017.4 · Cited by 231
Targeting immune cells for cancer therapy
Gun, S. Y., Lee, S. W. L., Sieow, J. L., & Wong, S. C. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101174 · Cited by 237
Cancer and Heart Disease: Associations and Relations
de Boer, R. A., Meijers, W. C., van der Meer, P., & van Veldhuisen, D. J. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1539 · Cited by 229
Metadata
- Authors
- Pardoll, D. M.
- Affiliations
- Johns Hopkins University (US)
- Corresponding author
- Pardoll, Drew M.
- ORCID
- Pardoll, Drew M.
- Venue
- Nature Reviews Cancer
- Published
- 2012-03-22
- Volume
- 12
- Issue
- 4
- Pages
- 252-264
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- PMC
- PMC4856023
- OpenAlex
- W2066671159
- Cited by
- 13,838
- References
- 129
- Citations by year
- 2026: 652 · 2025: 910 · 2024: 1153 · 2023: 1202 · 2022: 1302 · 2021: 1456 · 2020: 1409 · 2019: 1236 · 2018: 1197 · 2017: 1146 · 2016: 897 · 2015: 647 · 2014: 339 · 2013: 240 · 2012: 39
- FWCI
- 41.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Melanoma Research Alliance
- Hussman Foundation
- National Cancer Institute (P30CA021765, P30CA006973)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- immune checkpoint, cancer immunotherapy, immune checkpoint blockade, CTLA-4, PD-1, tumor immune evasion, antitumor immunity, self-tolerance, ligand-receptor interactions, antibody therapy, combination therapy, immune resistance
- MeSH terms
- Animals, Antigens, Neoplasm, Clinical Trials as Topic, Humans, Immunotherapy, Neoplasms, Tumor Escape, Cancer Vaccines, Molecular Targeted Therapy, CTLA-4 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
